Immune response in the mutant diabetic C57BL/Ks-dt+ mouse. Discrepancies between in vitro and in vivo immunological assays - PubMed (original) (raw)

Comparative Study

Immune response in the mutant diabetic C57BL/Ks-dt+ mouse. Discrepancies between in vitro and in vivo immunological assays

G Fernandes et al. J Clin Invest. 1978 Feb.

Abstract

Cell-mediated and humoral immune responses of mutant diabetic db+/db+ mice were evaluated using in vivo and in vitro immunological assays. When compared to lean, nondiabetic db+/m+ or m+/m+ mice, db+/db+ mice demonstrated markedly altered in vivo immune responses characterized by a significantly diminished ability to reject allogeneic skin grafts, a markedly diminished capacity to generate cytotoxic cells after sensitization with allogeneic EL-4 lymphoma cells and a significantly enhanced plaque-forming cell response to sheep erythrocytes. In contrast, spleen cells from db+/db+ mice demonstrated only minimal alterations in in vitro responses to mitogens and allogeneic cells and no alteration in their capacity to generate an in vitro plaque-forming cell response. The spleens and thymuses of db+/db+ mice weighed significantly less than organs from db+/db+ mice. In addition, thymuses from db+/db+ mice demonstrated a marked deficiency in in vivo [125I]UdR uptake. These data suggest that the altered metabolic status of the diabetic host influences immune function in vivo possibly due to abnormal function of lymphocyte subpopulations.

PubMed Disclaimer

References

    1. J Clin Invest. 1975 Oct;56(4):769-80 - PubMed
    1. Science. 1966 Sep 2;153(3740):1127-8 - PubMed
    1. Diabetes. 1974 Jan;23(1):9-15 - PubMed
    1. Clin Immunol Immunopathol. 1974 Apr;2(3):395-403 - PubMed
    1. Diabetologia. 1970 Jun;6(3):252-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources